Abbott Laboratories (ABT)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
| 12-2019 | 09-2019 | 06-2019 | 03-2019 | 12-2018 | |
| Cash Flows From Operating Activities | |||||
| Net Income | 3,687,000 | 2,638,000 | 1,678,000 | 672,000 | 2,368,000 |
| Depreciation Amortization | 3,014,000 | 2,258,000 | 1,504,000 | 753,000 | 3,310,000 |
| Accounts receivable | -275,000 | -357,000 | -335,000 | -170,000 | -190,000 |
| Other Working Capital | -1,331,000 | -1,087,000 | -875,000 | -456,000 | -148,000 |
| Other Operating Activity | 1,041,000 | 268,000 | -200,000 | -87,000 | 960,000 |
| Operating Cash Flow | $6,136,000 | $3,720,000 | $1,772,000 | $712,000 | $6,300,000 |
| Cash Flows From Investing Activities | |||||
| Change In Deposits | N/A | -22,000 | 2,000 | 2,000 | N/A |
| PPE Investments | -1,638,000 | -1,204,000 | -803,000 | -335,000 | -1,394,000 |
| Net Acquisitions | -122,000 | -123,000 | -112,000 | -78,000 | -6,000 |
| Purchase Of Investment | -103,000 | N/A | N/A | N/A | -131,000 |
| Sale Of Investment | 21,000 | N/A | N/A | N/A | 73,000 |
| Other Investing Activity | 27,000 | 23,000 | 19,000 | 15,000 | 102,000 |
| Investing Cash Flow | $-1,815,000 | $-1,326,000 | $-894,000 | $-396,000 | $-1,356,000 |
| Cash Flows From Financing Activities | |||||
| Change In Short Term Borrowing | N/A | 52,000 | 40,000 | 13,000 | -26,000 |
| Debt Issued | 1,842,000 | 0 | 0 | N/A | 4,009,000 |
| Debt Repayment | -3,441,000 | -523,000 | -521,000 | -500,000 | -12,433,000 |
| Common Stock Issued | 298,000 | 291,000 | 244,000 | 127,000 | 271,000 |
| Common Stock Repurchased | -718,000 | -222,000 | -221,000 | -217,000 | -238,000 |
| Dividend Paid | -2,270,000 | -1,702,000 | -1,133,000 | -565,000 | -1,974,000 |
| Financing Cash Flow | $-4,289,000 | $-2,104,000 | $-1,591,000 | $-1,142,000 | $-10,391,000 |
| Exchange Rate Effect | -16,000 | -43,000 | 6,000 | 4,000 | -116,000 |
| Beginning Cash Position | 3,844,000 | 3,844,000 | 3,844,000 | 3,844,000 | 9,407,000 |
| End Cash Position | 3,860,000 | 4,091,000 | 3,137,000 | 3,022,000 | 3,844,000 |
| Net Cash Flow | $16,000 | $247,000 | $-707,000 | $-822,000 | $-5,563,000 |
| Free Cash Flow | |||||
| Operating Cash Flow | 6,136,000 | 3,720,000 | 1,772,000 | 712,000 | 6,300,000 |
| Capital Expenditure | -1,638,000 | -1,204,000 | -803,000 | -335,000 | -1,394,000 |
| Free Cash Flow | 4,498,000 | 2,516,000 | 969,000 | 377,000 | 4,906,000 |